Guthrie M, Cardenas D, Eschbach J W, Haley N R, Robertson H T, Evans R W
Department of Rehabilitation Medicine, University of Washington, Seattle 98195.
Clin Nephrol. 1993 Feb;39(2):97-102.
The strength, endurance, and functional status of 15 anemic (HCT 21.2 +/- 4.6) hemodialysis patients was quantified prior to the administration of erythropoietin (epoetin) and after the anemia was partially corrected (HCT 35.4 +/- 2.3). Subjects showed significant increases in strength, measured isometrically (p < .01) and isokinetically (p < .01 at four of five speeds). They also demonstrated improved endurance and rated their functional ability higher. Anemia contributes to significant debilitation in hemodialysis patients and, when reversed with epoetin therapy, results in significantly improved muscle function and endurance.
对15名贫血（血细胞比容21.2 +/- 4.6）的血液透析患者在给予促红细胞生成素（依泊汀）之前以及贫血得到部分纠正后（血细胞比容35.4 +/- 2.3）的力量、耐力和功能状态进行了量化。受试者的力量显著增加，等长测量时（p <.01）以及等速测量时（五种速度中的四种速度下p <.01）均如此。他们还表现出耐力改善，并且对自己功能能力的评分更高。贫血会导致血液透析患者出现明显的身体衰弱，而通过依泊汀治疗逆转贫血后，肌肉功能和耐力会得到显著改善。
